The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies.

Analysts estimate that Eli Lilly will report an earnings per share (EPS) of $5.96. The market awaits Eli Lilly's announcement ...

The board of directors of (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...

Eli Lilly and Company announced a definitive agreement to acquire Aderum Biotechnologies and its leading candidate Ixo-vec. 1 Lilly is expected to pay $3.56 per share, in cash, along with up to $1.78 ...

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also ...

Investing.com - Eli Lilly has lifted its full-year financial forecasts, fueled by its mega-popular obesity treatments which helped the drugmaker deliver better-than-anticipated third-quarter results.

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...